מדד נזילות מהירה: Greenwich LifeSciences Inc (GLSI)

Greenwich LifeSciences (GLSI), a developer of immunotherapy for breast cancer, is currently in the final stage of clinical trials; consequently, the business relies on external investment in the absence of profit, with the indicator standing at 1.51. The price action helps track the asset's condition. The company's prospects are based on the long-term patent protection of its vaccines, while high patient confidence is driven by the success of preliminary research.

Professional selection of resilient assets begins by verifying a company's ability to meet immediate obligations. This metric excludes illiquid inventories, focusing exclusively on cash and accounts receivable. By analyzing short-term liquidity monitoring, an investor assesses the business's actual margin of safety. For Greenwich LifeSciences (GLSI), this is critical, as financial autonomy ensures the company's survival until the completion of final GP2 immunotherapy trials.